Evidence map›Paper›PMID 32284923›Full record

ArticleAfrican journal of laboratory medicine2020

H3Africa partnerships to empower clinical research sites to generate high-quality biological samples.

Talishiea Croxton, Ndidi Agala, Emmanuel Jonathan, Olasinbo Balogun, Petronilla J Ozumba, Enzenwa Onyemata, Shefiya Lawal, Manmak Mamven, Samuel Ajayi, Sylvia E Melikam and 6 more

Abstract read
In one paragraph

Article in African journal of laboratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Talishiea CroxtonInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-3095-3817
Ndidi AgalaInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID 0000-0002-2814-8651
Emmanuel JonathanInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-6284-8849
Olasinbo BalogunInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-9411-2983
Petronilla J OzumbaInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-8243-9647
Enzenwa OnyemataInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0002-8566-5444
Shefiya LawalDepartment of Internal Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria.ORCID https://orcid.org/0000-0001-7030-7954
Manmak MamvenDepartment of Internal Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-3229-6689
Samuel AjayiDepartment of Medicine, University of Abuja Teaching Hospital, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-4395-9222
Sylvia E MelikamDepartment of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID https://orcid.org/0000-0002-8156-4195
Mayowa OwolabiCenter for Genomic and Precision Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID https://orcid.org/0000-0003-1146-3070
Bruce OvbiageleDepartment of Neurology, University of Ghana Medical School, Accra, Ghana.ORCID https://orcid.org/0000-0003-3527-8857
Dwomoa AduDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, United States.ORCID https://orcid.org/0000-0002-2606-2117
Akinlolu OjoDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.ORCID https://orcid.org/0000-0002-5198-9854
Christine M BeiswangerCoriell Institute for Medical Research, Camden, New Jersey.ORCID https://orcid.org/0000-0003-3162-568X
Alash'le AbimikuInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID https://orcid.org/0000-0003-2213-0204

Funding

H3Africa Kidney Disease Research NetworkU54HG006939 · NHGRI · NOGUCHI MEMORIAL INSTITUTE / MEDICAL RES · PI ADU, DWOMOA, OJO, AKINLOLU OLUSEUN · 2012 to 2017
$6.1M
H3Africa Kidney Disease Research Network- Collaborative CentersU54DK116913 · NIDDK · COLLEGE OF HEALTH SCIENCES, UNIVERSITY OF GHANA · PI ADU, DWOMOA, OJO, AKINLOLU OLUSEUN · 2017 to 2021
$4.1M
IHVN H3 Africa Biorepository InitiativeUH3HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2015 to 2018
$2.9M
Institute of Human Virology H3Africa Biorepository (I-HAB) ADMIN SUPPLEMENTU24HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2019 to 2022
$2.3M
IHVN H3 Africa Biorepository InitiativeUH2HG007008 · NHGRI · INSTITUTE OF HUMAN VIROLOGY · PI ABIMIKU, ALASH'LE G. · 2012 to 2014
$811k
NHGRI NIH HHS U24 HG007008NHGRI NIH HHS U54 HG006939NHGRI NIH HHS UH2 HG007008NHGRI NIH HHS UH3 HG007008NIDDK NIH HHS U54 DK116913
6 · The paper itself

Abstract

backgroundThe Institute of Human Virology Nigeria (IHVN) - Human Heredity and Health in Africa (H3Africa) Biorepository (I-HAB) seeks to provide high-quality biospecimens for research. This depends on the ability of clinical research sites (CRS) - who provide biospecimens - to operate according to well-established industry standards. Yet, standards are often neglected at CRSs located in Africa. Here, I-HAB reports on its four-pronged approach to empower CRSs to prepare high-quality biospecimens for research.

objectivesI-HAB sought (1) to assess a four-pronged approach to improve biobanking practices and sample quality among CRSs, and (2) to build human capacity.

methodsI-HAB partnered with two H3Africa principal investigators located in Nigeria and Ghana from August 2013 through to May 2017 to debut its four-pronged approach (needs assessment, training and mentorship, pilot, and continuous quality improvement) to empower CRSs to attain high-quality biospecimens.

resultsClose collaborations were instrumental in establishing mutually beneficial and lasting relationships. Improvements during the 12 months of engagement with CRSs involved personnel, procedural, and supply upgrades. In total, 51 staff were trained in over 20 topics. During the pilot, CRSs extracted 50 DNA biospecimens from whole blood and performed quality control. The CRSs shipped extracted DNA to I-HAB and I-HAB that comparatively analysed the DNA. Remediation was achieved via recommendations, training, and mentorship. Preanalytical, analytical and post-analytical processes, standard operating procedures, and workflows were systematically developed.

conclusionPartnerships between I-HAB and H3Africa CRSs enabled research sites to produce high-quality biospecimens through needs assessment, training and mentorship, pilot, and continuous monitoring and improvement.

Indexed as

Africabiobankbiotechnologydeveloping countrytraining

Identifiers

PMID32284923
PMCPMC7136697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.